ASH 2024 Insights: MRD-Guided Ibrutinib and Venetoclax vs. FCR in Untreated Intermediate-Risk CLL - Final Results From the ERADIC Trial From the Filo Group | VuMedi

Find latest CLL videos · 200+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

This video is featured in the 2024 ASH Annual Meeting Insights Hub

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: MRD-Guided Ibrutinib and Venetoclax vs. FCR in Untreated Intermediate-Risk CLL - Final Results From the ERADIC Trial From the Filo Group

By 2024 ASH Annual Meeting Insights Hub FEATURING Anne Sophie Michallet

By 2024 ASH Annual Meeting Insights Hub FEATURING Anne Sophie Michallet

6 views

April 3, 2025

Comments 0

Login to view comments. Click here to Login